However, despite treatment with current antifibrotic medications, most patients with pulmonary fibrosis still suffer from ...

Namilumab failed to show treatment benefit in patients with pulmonary sarcoidosisFurther development of namilumab for the treatment of ...

The table below is a review of notable updates that occurred in November 2024 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.

Keros’ elritercept has shown promising efficacy signals in myelofibrosis and myelodysplastic syndromes and could pose a ...

The Rohingya refugee crisis is one of the most severe humanitarian emergencies of recent decades. The crisis stems from a ...